Navigation Links
Crestor Patent Invalidity Evidence Uncovered By Article One Partners Community
Date:7/1/2009

nowledge and referral networks of our Advisors, this evidence known as prior art can be discovered. Prior art may come from published content anywhere in the world and in any language, including: previous patents; news or academic publications; non-digitized documents such as textbooks; or any public document provided to others, including conference or academic papers and business materials. Article One and its Clients analyze the prior art to determine whether it can show patents to be legitimized or invalid.

If Article One or its Clients determine that the submissions of its Advisors can show patents to be invalid, Advisors earn up to $50,000. Advisors who actively build the community also earn premium compensation in a Profit Sharing Plan, distributing approximately five percent (5%) of Article One's net annual profit. The result is a highly-rewarded community providing a second, citizen's review of U.S. patents to justify monopoly pricing for true innovation and energize U.S. patent reform. To learn more about Article One Partners, or to become a member of our community, please visit www.ArticleOnePartners.com .

Article One Partners and AOP are service marks of Article One Partners, LLC. All other product and company names are the trademarks and property of their respective owners.

(C) 2009. Article One Partners, LLC. All rights reserved.


'/>"/>
SOURCE Article One Partners, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. CRESTOR(R) Now Indicated to Slow the Progression of Atherosclerosis in Patients With Elevated Cholesterol
2. Analyst Available to Comment on New JUPITER Study That Shows AstraZenecas Crestor Significantly Reduces CV Risk
3. CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study
4. As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
5. Video: CRESTOR(R) Reduced Risk of Blood Clots in the Veins
6. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
7. Spectranetics to Appeal Decision in Patent Litigation
8. Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs
9. Actavis Confirms its Patent Challenge of Kings Avinza(R)
10. PartsSource Awarded US Patent for PartsFinder(TM) Application
11. Barr Confirms Patent Challenge of UROXATRAL(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2014)... pre-diabetes in the United States have nearly doubled since 1988, ... Public Health, with obesity apparently to blame for the surge. ... has not hit all groups equally, with alarming increases in ... new research reported in the April 15, 2014 issue of ...
(Date:4/15/2014)... School of Medicine have identified a mechanism that explains why ... why the virus is able to persist in the body ... an estimated 200 million people worldwide, attacks the liver cells, ... ability to fight infection. It does this by altering cells ...
(Date:4/14/2014)... and American Associations for Dental Research (IADR/AADR) have published ... Oral, and Craniofacial Manifestations." The complete review by researchers ... Michael Collins, Brian L. Foster, Rachel I. Gafni, Janice ... J. Timothy Wright is published in the OnlineFirst portion ...
(Date:4/14/2014)... Orange, NJ. April 10, 2014. John DeLuca, PhD, and ... Biogen Idec to study how persons with multiple sclerosis ... Use of Actual Reality to Measure Everyday Life Functional ... this research. Dr. DeLuca is senior VP of Research ...
(Date:4/14/2014)... A new study identifies a molecule that is a ... molecule could be an important target for colorectal cancer treatment ... of microRNA-135b (miR-135b) in two animal models and human tumors ... was led by researchers at The Ohio State University Comprehensive ...
Breaking Medicine News(10 mins):Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Breaking bad mitochondria 2Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2
... an 8-year-old boy,living with epilepsy, and his mother Amy ... Inc., the exclusive sponsor of Canine,Assistants seizure response dogs. ... him to play sports, take,music lessons, and learn Tae ... seizure when his parents are not around is still ...
... Mass., April 16 Xceed Molecular, a ... analysis,systems, announced that the University of Florida ... work with primary researchers,Charles Joel Rosser, MD ... of Surgery), to perform initial verification and ...
... April 16 Consumer,Watchdog today joined L.A. City ... that health insurer Blue Cross engaged in unfair,business ... patients,after they got sick., The practice -- ... hundreds,of patients who have been left uninsured, uninsurable, ...
... Pa., April 16 Law Offices of ... potential claims against Inverness,Medical Innovations, Inc. ("Inverness ... securities law violations by Inverness Medical and,certain ... Company,s secondary,public offering on or about November ...
... Participating Courtesy of TriWest -, PHOENIX, April ... protect America,s freedoms in Iraq and Afghanistan, Marines,Chris ... injuries diminish,their spirits. Both received prosthetic limbs, returned ... courtesy of TriWest Healthcare Alliance., As members ...
... Help Build Healthy Communities, VICTORVILLE, Calif., April ... the Victorville Earth Day Eco Tote giveaway.,On Tuesday, ... offices will be handing out recyclable Eco Totes ... the Reduce, Reuse, Recycle program, Heritage Victor Valley,Medical ...
Cached Medicine News:Health News:Young Boy With Epilepsy to Gain Independence With New Seizure Response Dog From Canine Assistants 2Health News:Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer 2Health News:Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer 3Health News:Consumer Watchdog Applauds L.A. City Attorney's Efforts to Reinstate Cancelled Blue Cross Patients; Urges State HMO Regulator to Do Same 2Health News:Wounded Marines Running Their Way to Recovery at Fourth Annual Pat's Run 2Health News:Wounded Marines Running Their Way to Recovery at Fourth Annual Pat's Run 3
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: HTWR ... support technologies that are revolutionizing the treatment of advanced ... the fourth quarter of 2013 will be approximately $53 ... million. "Our full-year revenue growth of 87% ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... VIENNA , April 23, 2010 AFFiRiS ... II clinical testing.,It may therefore be possible to confirm the ... start of this efficacy study comes only five,months after the ... in several disease areas and is currently developing a total ...
... LONDON , April 23, 2010 , , ... Managing uncertainty; A Migraine For Pharma Forecasters , , , ... has its up,s and down,s, with new markets,and products proving more complex and requiring sophisticated approaches to,forecast ... Dealing with uncertainties is no easy task. With ...
Cached Medicine Technology:AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 2AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 3AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 4MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 2MarketsandMarkets Partners With Eyeforpharma For The Pharma Forecasting Excellence Europe 2010 Summit 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: